Date: 2015-12-15
Type of information: Nomination
Compound:
Company: Oxford Biomedica (UK)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On December 15, 2015, Oxford BioMedica , a leading gene and cell therapy group, announced that Dr. Lorenzo Tallarigo will be appointed as Non-Executive Chairman of the Group on 1 February 2016. From 2008 to 2014 Dr.Tallarigo was a member of the Board, and Chairman from 2011, of Intercept Pharmaceuticals, a biopharmaceutical company focused on the development and commercialisation of novel therapeutics to treat liver diseases. From 2009 to 2014, Dr. Tallarigo also held the position of Chief Executive Officer at Genextra, a holding company focused on identifying innovative research and projects in life sciences to develop novel treatments and tools by creating successful business ventures, including a 30 per cent. shareholding in Intercept Pharmaceuticals. Under his leadership at Genextra, where he continues as a current Board member, Dr. Tallarigo raised finance to support the activities of several healthcare companies acting in a variety of therapeutic areas.From 1985 to 2008, Dr. Tallarigo worked at Eli Lilly, where he held various positions in areas of clinical research, pharmaceutical product management and marketing and general management, and latterly as its President of international operations. During his latter role at Eli Lilly, Dr. Tallarigo was responsible for $8 billion of revenues and $4 billion in profits, covering 140 countries and managing 12,000 employees. One-third of Dr Tallarigo’s fees as Chairman, after tax, will be used to purchase shares in Oxford Biomedica on a monthly basis at the prevailing market price. At times this will require shares to be purchased during prohibited periods, as permitted by paragraph 17 of the Model Code to the Listing Rules. There are no further details to be disclosed on the appointment of Dr Tallarigo required under the Financial Services Authority Listing Rule 9.6.13. Nick Rodgers, the current Chairman of Oxford BioMedica, will remain on the Board of Oxford BioMedica as a Non-Executive director for a transitional period until 30 April 2016.
Financial terms:
Latest news:
